In today’s feature article, we talk with Ziyad Al-Aly, MD, of the Institute for Public Health in Washington, DC, who describes treating long-haulers as “America’s next big health crisis.”
Results of a recent study suggest possible factors that need to be considered when preparing patients for hospital discharge.
Study findings suggest that the ratio of interleukin-10 to tumor necrosis factor-alpha produced by transitional-1 B cells can predict renal allograft outcomes with a lead time of about 8 months.
In patients with acidemia, hypobicarbonatemia conferred a considerable risk of kidney failure requiring renal replacement therapy after adjusting for potential confounders.
A simplified creatinine index reflects the creatinine generation rate of individual patients on hemodialysis.
Researchers suggest appropriate monitoring and use of standard treatment algorithms to identify and treat toxic effects after a rechallenge after irAEs in patients receiving ICI therapy.
Men with metastatic castration-resistant prostate cancer and symptomatic bone metastases had longer survival times when they received radium-223 as first-line therapy compared with those who received the drug as third-line therapy.
The authors of new review say the results of the JCOG0401 trial suggest that standard hormonal therapy alone vs salvage radiotherapy is not an appropriate management strategy for recurrence after radical prostatectomy.
Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.
The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
